BioCentury
ARTICLE | Clinical News

Sandoz starts Phase III testing of Humira biosimilar

December 19, 2013 2:02 AM UTC

Sandoz began an international Phase III trial to evaluate a biosimilar of Humira adalimumab in patients with moderate to severe plaque-type psoriasis. The generics unit of Novartis AG (NYSE:NVS; SIX:NOVN) said the trial will support registration in the U.S. and EU. AbbVie Inc. (NYSE:ABBV) markets Humira in the U.S. and EU for a range of autoimmune disorders, including Crohn's disease (CD) and rheumatoid arthritis (RA). Eisai Co. Ltd. (Tokyo:4523) co-promotes Humira in Japan, Korea and Taiwan. ...